FDA approves Helimbra, new drug to prevent bleeding episodes in Hemophilia A patients

By
Amy J. Smith, Cosmetologist
-
0
fda approves helimbra new drug to prevent bleeding episodes in hemophilia a patients

The U.S. Food and Drug Administration (FDA) has approved Helimbra (Emicizumab-kxwh) for preventing or reducing bleeding episodes in some patients of Hemophilia A.

People with Hemophilia A generally lack a gene that is responsible for producing blood-clotting factor, called Factor VIII. This drug is administered in patients with antibodies, known as Factor VIII inhibitors.

According to FDA, approximately 5000 babies born in the U.S. are affected by hemophilia, and out of these, 80% have Hemophilia A. Also, this disease is more common in male babies.

In Hemophilia A, patients generally experience bleeding in the joints, which can cause severe damage. In some cases, the patients start developing antibodies against the standard treatment for bleeding episodes.

ADVERTISEMENT

Dr. Richard Pazdur, Acting Director, FDA’s Office of Hematology and Oncology Products, told that the approval for Helimbra is a great preventive measure to prevent bleeding episodes in patients with hemophilia A and Factor VIII inhibitors. He also added that when patients were treated with Helimbra, they showed improvement in their physical activities.

A few side effects of the drug was also reported like reaction on the site of injection, headache and joint pain.
FDA said, “The drug’s label includes a boxed warning of possible blood clots among recipients who also are given anti-bleeding medication.”

 

Source: drugs.com

SHARE ON
FacebookTwitterGoogle+Pinterest
SHARE ON
FacebookTwitterGoogle PlusPinterest

RELATED ARTICLESMORE FROM AUTHOR

FDA Warns: Male Enhancement Products May Be Dangerous

FDA Warns, Male Enhancement Products May Be Dangerous

FDA has furnished a warning letter regarding the male enhancement products which are unapproved and available at gas stations. It may seem fun to try those inexpensive but unreliable...

fda committee recommends first marijuana-derived drug

FDA Committee Recommends First Marijuana-Derived Drug

First prescription cannabidiol medicine has been voted by Federal Advisors for recommendation to get approval for treating epilepsy. Even the US. FDA advisory committee has voted in unison for...

biosimilar drug ogviri approved by fda for breast and stomach cancer

‘Biosimilar’ drug Ogviri approved by FDA for breast and stomach cancer

For the treatment of certain breast and stomach cancers, the U.S. Food and Drug Administration (FDA) recently approved Ogiviri (tastuzumab-dkst), which is the nation's first biosimilar drug. FDA said...

monthly dose of buprenorphine for treating opioid addiction approved by fda

Monthly dose of Buprenorphine for treating opioid addiction, approved by FDA

U.S. Food and Drug Administration has approved a once in a month injection of Buprenorphine for the treatment of opioid addiction. Dr. Scott Gottlieb, FDA Commissioner said that there...

fda approves nerve stimulator for people facing opioid withdrawal symptoms

FDA approves nerve stimulator for people facing opioid withdrawal symptoms

For reducing the symptoms of opioid withdrawal, a novel device has been approved by the U.S. Food and Drug Administration (FDA). This is an electrical nerve stimulator. Innovative Health Solutions...

fda approves mepsevii for sly syndrome a rare enzyme disorder

FDA approves Mepsevii for Sly syndrome – a rare enzyme disorder

For the treatment of a rare, genetic disease, known as mucopolysaccharidosis type VII or Sly syndrome, a drug, named Mepsevii has been recently approved by the U.S. Food and...